Evidence map›Paper›PMID 25761698›Full record

ArticleAmerican journal of physiology. Regulatory, integrative and comparative physiology2015

Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats.

Apurva A Javkhedkar, Yasmir Quiroz, Bernardo Rodriguez-Iturbe, Nosratola D Vaziri, Mustafa F Lokhandwala, Anees A Banday

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Regulatory, integrative and comparative physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Cocoa Shell Extract Restores Redox Balance in Developmental Hypertension in Male Rats: Roles of Nrf2, SOD2 and p-eNOS.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  8. Reactive oxygen species in hypertension.Nature reviews. Cardiology · 2025
    Review
  9. Natural Products in the Clinical Management of Metabolic Syndrome.Handbook of experimental pharmacology · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. NRF2 in kidney physiology and disease.Physiological reports · 2024
    Review
  15. Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Oxidative Stress, Antioxidants and Hypertension.Antioxidants (Basel, Switzerland) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Apurva A JavkhedkarHeart and Kidney Institute, College of Pharmacy, University of Houston, Houston Texas;
Yasmir QuirozHospital Universitario, Universidad del Zulia and Instituto Venezolano de Investigaciones Científicas-Zulia, Maracaibo, Venezuela; and.
Bernardo Rodriguez-IturbeHospital Universitario, Universidad del Zulia and Instituto Venezolano de Investigaciones Científicas-Zulia, Maracaibo, Venezuela; and.
Nosratola D VaziriDivision of Nephrology and Hypertension, University of California, Irvine, California.
Mustafa F LokhandwalaHeart and Kidney Institute, College of Pharmacy, University of Houston, Houston Texas;
Anees A BandayHeart and Kidney Institute, College of Pharmacy, University of Houston, Houston Texas; abanday@uh.edu.
University of Houston · USInstituto Venezolano de Investigaciones Científicas · VEUniversity of California, Irvine · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Transcriptional regulation: renal dopamine D1 receptors in HTN & oxidative stressR01DK098509 · NIDDK · UNIVERSITY OF HOUSTON · PI LOKHANDWALA, MUSTAFA F. · 2013 to 2016
$1.3M
NCATS NIH HHS UL1 TR001414NIDDK NIH HHS DK-098509NIDDK NIH HHS R01 DK098509
6 · The paper itself

Abstract

Compelling evidence supports the role of oxidative stress and renal interstitial inflammation in the pathogenesis of hypertension. Resveratrol is a polyphenolic stilbene, which can lower oxidative stress by activating the transcription factor nuclear factor-E2-related factor-2 (Nrf2), the master regulator of numerous genes encoding antioxidant and phase II-detoxifying enzymes and molecules. Given the role of oxidative stress and inflammation in the pathogenesis of hypertension, we conducted this study to test the hypothesis that long-term administration of resveratrol will attenuate renal inflammation and oxidative stress and, hence, progression of hypertension in the young spontaneously hypertensive rats (SHR). SHR and control [Wistar-Kyoto (WKY)] rats were treated for 9 wk with resveratrol or vehicle in their drinking water. Vehicle-treated SHR exhibited renal inflammatory injury and oxidative stress, as evidenced by glomerulosclerosis, tubulointerstitial injury, infiltration of inflammatory cells, and increased levels of renal 8-isoprostane and protein carbonylation. This was associated with reduced antioxidant capacity and downregulations of Nrf2 and phase II antioxidant enzyme glutathione-S-transferase (GST). Resveratrol treatment mitigated renal inflammation and injury, reduced oxidative stress, normalized antioxidant capacity, restored Nrf2 and GST activity, and attenuated the progression of hypertension in SHR. However, resveratrol had no effect on these parameters in WKY rats. In conclusion, development and progression of hypertension in the SHR are associated with inflammation, oxidative stress, and impaired Nrf2-GST activity in the kidney. Long-term administration of resveratrol restores Nrf2 expression, ameliorates inflammation, and attenuates development of hypertension in SHR. Clinical studies are needed to explore efficacy of resveratrol in human hypertension.

Indexed as

AnimalsAntioxidantsBlood PressureBody WeightDrinkingEatingHypertensionInflammationKidneyMaleNF-E2-Related Factor 2Oxidative StressRatsRats, Inbred SHRRats, Inbred WKYResveratrolAntioxidantsNfe2l2 protein, ratNF-E2-Related Factor 2ResveratrolStilbeneshypertensionoxidative stressproximal tubules

Identifiers

PMID25761698
PMCPMC4459926
OpenAlexW1973825375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.